

Horizon 2020 'Health, demographic change and wellbeing'

> Open Info Day -Horizon 2020 'Health, demographic change and wellbeing' Brussels, 22 Nov 2013

#### **Disclaimer**

Pending formal adoption by the EU of the Horizon 2020 legal texts, the content of these slides is not definitive and so should not be taken as such, nor used or referred to as such in any way or for any purpose



## Horizon 2020 - what's new?

- A single programme bringing together three separate programmes/initiatives\*
- Coupling research to innovation from research to retail, all forms of innovation
- Focus on societal challenges facing European society e.g. health and ageing, clean energy and transport
- **Simplified access,** for all companies, universities, institutes in all EU countries and beyond

The 7<sup>th</sup> Research Framework Programme (FP7), innovation aspects of Competitiveness and Innovation Framework Programme (CIP), EU contribution to the European Institute of Innovation and Technology (EIT)



## **Building on experience**


**FP7 'Health' – the largest** multi-national fund...

- ...for collaborative research, global consortia, and publicprivate co-operation
- ...to fund excellent applied health and ageing research and innovation
- ...to bring together leading players from Europe and across the globe
- ...to tackle key European and global health challenges





## **The challenges**



- Ageing population
- Increased disease burden
- Unsustainable and unequal health & care systems
- Health & care sector under pressure to reform



# Recap: the 'Health, demographic change and wellbeing' challenge

#### **Proposed funding 2014-2020 (million EUR)**

Health, demographic change and wellbeing	7 472
Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the Bioeconomy	3 851
Secure, clean and efficient energy *	5 931
Smart, green and integrated transport	6 339
Climate action environment resource efficiency and	3 081



## **Strategic Initiatives**



Innovative Medicines Initiative 2 www.imi.europa.eu



European Innovation Partnership on Active and Healthy Ageing https://webgate.ec.europa.eu/eipaha



Active and Assisted Living 2 www.aal-europe.eu




European & Developing Countries Clinical Trials Partnership (EDCTP2) www.edctp.org



European Commission

### The Work Programme 2014/15 in brief





## A new approach



Commission







Understanding health, ageing & disease

Effective health promotion, disease prevention, preparedness and screening

**Improving diagnosis** 

Innovative treatments and technologies

Advancing active and healthy ageing

Integrated, sustainable, citizen-centred care

Improving health information, data exploitation and providing an evidence base for health policies and regulation



### **Understanding the call topics: example**

PHC 2 – 2015: Understanding diseases: system Specific challenge: The development of new improved understanding of the often very cor (bio) medicine approaches have the potential to t of a variety of biological and medical research da collaborative approach is required to assemble th biology, medicine, mathematics, computational t medicine approaches.

<u>Scope:</u> Proposals should focus on new avenues phenotypes in multifactorial diseases and/or development/optimisation and/or application of s of biomedical and clinical data to produce or refi computational and mathematical approaches. Th validated in well-phenotyped patient cohorts, tak potential thoroughly investigated.

The Commission considers that proposals reques EUR 4 and 6 million would allow this speci Nonetheless, this does not preclude submission amounts.

Expected impact: This will provide:

- Leverage of existing investments in Eur
- New directions for better disease detection
- Systems medicine tools and approaches t which represent an improvement over e

<u>Type of action:</u> Research and Innovation action

'PHC 2 - 2015'

## 'Specific challenge'

'Scope'

'Expected impact'

## 'Type of action'





## **Unravelling health and disease**

 Determinants, risk factors and pathways of diseases (2014)

**Determinants and pathways of healthy and active ageing (2014)** 

- Systems medicine approaches (2015)
- Common mechanisms of diseases and potential co-morbidities (2015)



Effective health promotion, disease prevention, preparedness and screening

## From "omics" ... to prevention

- Inter-sector cooperation for environment- and healthbased interventions (2015)
- Translating -omics into prevention and health promotion (2014)
- Evaluating existing screening and prevention programmes (2014)
- Control of infectious epidemics through rapid pathogen identification (2014)
- Vaccine platforms for TB (2014) and HIV (2015)



## Improving diagnosis

## In biomarkers we trust ... and in novel diagnostic tools

- In vitro devices, assays and platforms (2014)
- In vivo medical imaging technologies (2015)
- Clinical validation of biomarkers (2014, 2015)
- SME focus



## Finding the cure ... and evaluating existing treatments

- Therapies for non-communicable diseases (2014) and rare diseases (2015)
- Tools and technologies for advanced therapies (2015)
- Clinical research on regenerative medicine (2014)
- Comparing and establishing effectiveness of health interventions in the elderly (2014) and children (2015)



**Innovative treatments and technologies** 

## **Adding more life to our years**

- Service robotics within assisted living environments (2014)
- Pilot projects on independent living with cognitive impairments (2014)
- Early risk detection and intervention (2015)
- Promoting mental wellbeing in the ageing population (2015)



Advancing active and healthy ageing

## The citizen in the centre

- New models for prevention oriented health and care systems (2014)
- Piloting personalised medicine in health and care systems (2015)
- Self-management of health and disease:
  - citizen engagement and mHealth for disease management (2014),
  - patient empowerment supported by ICT (2015)
  - based on predictive computer modelling (2015)



## The citizen in the centre (2)

- Public procurement of innovative eHealth services (2015)
- ICT systems for integrated care (2015)
- eHealth sectorial inducement prize (2015)



Improving health information, data exploitation and providing an evidence base for health policies and regulation

## **Big Data for research**

- Digital representation of health data to improve diagnosis and treatment (2015)
- Foresight for health policy development and regulation (2014)
- Advancing bioinformatics for clinical needs (2014)
- Improve predictive human safety testing (2015)
- eHealth interoperability (2014)







**Coordination and Support actions** 

## Support for European and International Initiatives

- European Innovation Partnership on Active and Healthy Ageing
- Global Alliance for Chronic Diseases (GACD) Diabetes (2014)
- Joint Programming Initiative 'More Years, Better Life's (2014)
- Joint Programming Initiative on neurodegenerative diseases (JPND, 2014)
- Global Research Collaboration for Infectious Disease Preparedness (2014)
- European Reference Networks (2015)





## **Completing the European Research Area**

- Joint Programming Initiative on neurodegenerative diseases (JPND, 2014)
- Translational cancer research (2014)
- Systems medicine for clinical needs (2014)
- Rare diseases (2014)
- 2015: Brain-related disorders, antimicrobial resistance, cardiovascular diseases



## **Next steps**

Adoption of work programme and publication of first calls for proposals	11 December 2013
Submission deadlines for your proposals	Two-stage: 11 March & 19 August All others: 15 April SME instrument: check Work Programme
Horizon 2020 national launch events	<b>Until January 2014</b> Full list: http://ec.europa.eu/research/horizon2020
National info days	Please check with your national contact points http://ec.europa.eu/research/participants/portal/page/nationalcontactpoint





The biggest public/private partnership in Life Science aiming to:

•Make drug R&D processes in Europe more innovative and efficient

Enhance Europe's competitiveness

Address key societal challenges

#### **Features:**


1:1 funding, joint decision making

•All EU funds go to SMEs, academia, patient organisations and regulatory agencies

•Large pharmaceutical industry, represented by EFPIA, contributes in-kind



European Commission



Call 10 application deadline 28 January 2014, 17:00:00 Brussels time Call 11 to be launched in December, indicative text on IMI website



#### Innovation

✓ Faster development of diabetes drugs through the first ever human pancreatic beta-cell line

✓ New models to better predict drug toxicity

✓ **New definition of severe asthma** which promises to unlock new therapies

✓The world's largest database of schizophrenia studies to develop targeted treatments

✓ Unprecedented collaboration for tackling antimicrobial resistance

### Research

✓ 483 scientific publications - Average citation impact is twice the world average

✓ 19% rank in the top quartile of journals in their specific research fields







## In the Pipeline: IMI2

Commission proposal from 10 July, legislative process ongoing Mission: create an even more powerful research and innovation machine – with broader objectives and a wider range of activities and partners Proposed budget from public and private partners: 3.45 Billion Euro equally shared Key objectives:

Pave the way for the breakthrough vaccines, medicines and treatments which we will need in the near future Enable top quality research and innovations with great public health benefits and commercial possibilities







## Thank you for your attention!

**Find out more:** www.ec.europa/research/horizon2020



## **Three priorities**

Excellent science

## Industrial Societal leadership challenges



## Excellent science

## **Proposed funding**

(million EUR, 2014-2020)\*

European Research Council (ERC)	
Frontier research by the best individual teams	13 095
Future and Emerging Technologies	
Collaborative research to open new fields of innovation	2 696
Marie Skłodowska-Curie actions (MSCA)	
Opportunities for training and career development	6 162
<b>Research infrastructures</b> (including e-infrastructure)	
Ensuring access to world-class facilities	2 488

All funding figures in this presentation are subject to the pending Multiannual Financial Framework Regulation by the EP and the Council





## Industrial leadership

## **Proposed funding**

(million EUR, 2014-2020)\*

Leadership in enabling and industrial technologies (LEITs) (ICT, nanotechnologies, materials, biotechnology, manufacturing, space)	13 557
Access to risk finance Leveraging private finance and venture capital for research and innovation	2 842
<b>Innovation in SMEs</b> Fostering all forms of innovation in all types of SMEs	616 + complemented by expected 20% of budget of societal challenges + LEITs and 'Access to risk finance' with strong SME focus

All funding figures in this presentation are subject to the pending Multiannual Financial Framework Regulation by the EP and the Council





## Societal challenges

## **Proposed funding**

(million EUR, 2014-2020)\*

Health, demographic change and wellbeing	7 472
Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the Bioeconomy	3 851
Secure, clean and efficient energy *	5 931
Smart, green and integrated transport	6 339
Climate action, environment, resource efficiency and raw materials	3 081
Inclusive, innovative and reflective societies	1 310
Secure societies	1 695
Science with and for society	462
Spreading excellence and widening participation	816

All funding figures in this presentation are subject to the pending Multiannual Financial Framework Regulation by the EP and the Council





## **More opportunities for SMEs**



- Integrated approach around 20% of the total budget for societal challenges and LEITs to go to SMEs
- **Simplification** of particular benefit to SMEs (e.g. single entry point)
  - A **new SME instrument** will be used across all societal challenges as well as for the LEITs
- A dedicated activity for research-intensive SMEs in 'Innovation in SMEs'
- 'Access to risk finance' will have a strong SME focus (debt and equity facility)







## **Getting you started faster**

- Single set of simpler and more coherent participation rules
- New balance between trust & control
- Just two funding rates for different beneficiaries and activities
- Single flat rate to calculate overhead or «indirect costs»
- Forthcoming financial regulation will make things simpler
- time-to-grant of 8 months

   (exceptions for the ERC and in duly
   justified cases







## EU International Strategy for Research & Innovation

Global Challenges International Science Innovation Opportunities



## **International cooperation**

- A priority
- Key goal: enhancing and focusing international cooperation in terms of areas and partners
- Horizon 2020 is open to participation from across the world
- Wanted: more involvement of international partners!
- Targeted actions across the entire programme
- Horizon 2020 Regulation and Rules for Participation apply





## **General opening**

- Horizon 2020 is open to participation from across the world
- Automatic funding:
  - Member States (including overseas departments and overseas territories)
  - Associated Countries
  - exhaustive list of countries in annex to work programme (but: no longer BRIC + Mexico in this list!)
- Participants from other countries only funded in exceptional cases:
  - when provision is made in the call text
  - bilateral agreement (e.g. Health challenge NIH)
  - when the Commission deems it essential (case by case assessment)





## **Proposal evaluation**

- Provisional Criteria & scoring – in the WP General Annex
- Proposal evaluation process involving at least 3 external experts per proposal in Commission Guidelines



# Award criteria: Research and Innovation Actions; Innovation Actions; SME instrument

## **1. Excellence**

- Ground-breaking nature (e.g. level of ambition, beyond the state-of-the-art, novel approach, addresses challenge, ...)
- Conceptually robust; trans-disciplinarity considered...



## Award criteria: Research and Innovacion Actions; Innovation Actions; SME instroment isiona/

2. Impact [...] extent to which project outputs contribute to:

- > The expected impacts listed in the work programme under the relevant topic;
- Enhancing innovation capacity and integration of new knowledge;
- Strengthening the competitiveness and growth of companies by developing innovations meeting the needs of European and global markets;
- Effectiveness of the proposed measures to communicate the project, disseminate and/or exploit the project results, and appropriate management of IPR.



# Award criteria: Research and Innovation Actions; Innovation Actions; SME instroment

## 3. Quality and efficiency of implementation

- Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks and resources;
- Competences, experience and complementarity of the individual participants, as well as of the consortium as a whole;
- Appropriateness of the management structures and procedures, including risk management.



## Scoring/weights/thresholds

Provisional As in FP7 each criterion scored out of 5; thresholds will be applied for each criterion and the total score, different depending on the call and action

Unlike FP7, for Innovation Actions and SME instrument...

- impact criterion weighted by factor of 1.5
- Impact considered first when scores equal



# **Priority of proposals with equal total score**



#### For each group of tied proposals

- First consider those that "fill gaps" in the WP
- Of those, look at score for 'excellence', then at score for 'impact'
  - (reverse for Innovation actions & SME instrument)
- If still equal, look at SME budget
- If still equal look at gender balance in key personnel
- If still equal, consider other factors (overall portfolio, wider H2020, EU objectives etc.)
- Then repeat for those that don't "fill gaps"

